TP53BP1 and neoplasm: Importantly, while PARP inhibitor treatment did not lead to a significant reduction in tumor weight inhibition (TWI), acetaldehyde inhibited the growth of allografts derived from Brca1−/−, 53BP1‐deficient cells by 54% (P < 0.001; Fig 7C).